Reduced colony formation of CD34+ CML cells in the presence of dasatinib was complemented upon administration of cytokines that provide survival signals via JAK2 [69]. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.